BRPI0808438A2 - Composto, composição farmacêutica, e, usos de uma composição farmacêutica, e de um composto. - Google Patents

Composto, composição farmacêutica, e, usos de uma composição farmacêutica, e de um composto. Download PDF

Info

Publication number
BRPI0808438A2
BRPI0808438A2 BRPI0808438-6A BRPI0808438A BRPI0808438A2 BR PI0808438 A2 BRPI0808438 A2 BR PI0808438A2 BR PI0808438 A BRPI0808438 A BR PI0808438A BR PI0808438 A2 BRPI0808438 A2 BR PI0808438A2
Authority
BR
Brazil
Prior art keywords
pyrimidin
triazolo
ethyl
furan
amine
Prior art date
Application number
BRPI0808438-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Allan R Moorman
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of BRPI0808438A2 publication Critical patent/BRPI0808438A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0808438-6A 2007-03-30 2008-03-28 Composto, composição farmacêutica, e, usos de uma composição farmacêutica, e de um composto. BRPI0808438A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US90910607P 2007-03-30 2007-03-30
US60/909106 2007-03-30
US12/056423 2008-03-27
US12/056,403 US7691869B2 (en) 2007-03-30 2008-03-27 Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
US12/056,423 US7723343B2 (en) 2007-03-30 2008-03-27 Adenosine A2A receptor antagonists
US12/056403 2008-03-27
PCT/US2008/058544 WO2008121748A2 (en) 2007-03-30 2008-03-28 Adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0808438A2 true BRPI0808438A2 (pt) 2014-07-29

Family

ID=39795488

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808438-6A BRPI0808438A2 (pt) 2007-03-30 2008-03-28 Composto, composição farmacêutica, e, usos de uma composição farmacêutica, e de um composto.

Country Status (12)

Country Link
US (2) US7691869B2 (https=)
EP (1) EP2129220A4 (https=)
JP (1) JP2010523497A (https=)
KR (1) KR20100014397A (https=)
CN (1) CN101652067A (https=)
AU (1) AU2008232690A1 (https=)
BR (1) BRPI0808438A2 (https=)
CA (1) CA2680075A1 (https=)
IL (1) IL201234A0 (https=)
MX (1) MX2009010223A (https=)
NZ (1) NZ578720A (https=)
WO (1) WO2008121748A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000743A2 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
JP5748659B2 (ja) 2008-06-10 2015-07-15 アッヴィ・インコーポレイテッド 新規な三環式化合物
WO2010065668A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
KR20120102724A (ko) 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
PE20121336A1 (es) * 2009-12-01 2012-11-03 Abbvie Inc Nuevos compuestos triciclicos
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
CN103261202B (zh) * 2010-09-24 2016-01-20 阿迪维纳斯疗法有限公司 作为腺苷受体拮抗剂的稠合三环化合物
WO2012149280A2 (en) * 2011-04-29 2012-11-01 Abbott Laboratories Novel tricyclic compounds
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN109641911B (zh) * 2016-08-19 2023-02-21 百时美施贵宝公司 seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法
DK3601296T3 (da) * 2017-03-30 2022-08-29 iTeos Belgium SA 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere
TW202039496A (zh) 2018-11-30 2020-11-01 美商默沙東藥廠 做為腺苷受體拮抗劑之9-經取代胺基三唑喹唑啉衍生物、醫藥組合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
EP0666079B1 (en) 1993-07-27 2001-11-07 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) * 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
SI1283839T1 (https=) 2000-05-26 2005-08-31 Schering Corp
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
CA2468649C (en) 2001-11-30 2009-03-10 Schering Corporation Adenosine a2a receptor antagonists
IL160133A0 (en) 2002-05-30 2004-06-20 King Pharmaceuticals Res & Dev Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
US20060128694A1 (en) 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
CL2004000847A1 (es) 2003-04-23 2005-03-11 Schering Corp Compuestos derivados de 2-alquinil o 2-alquenil-5amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-]pirimidina; composicion farmaceutica, y uso en el tratamiento de enfermedades del sistema nervioso central o un accidente cerebrovascular tal como depresion,
EP1745047B1 (en) 2004-04-21 2010-03-24 Schering Corporation Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
ATE538123T1 (de) 2005-09-19 2012-01-15 Schering Corp 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine

Also Published As

Publication number Publication date
EP2129220A4 (en) 2010-12-29
NZ578720A (en) 2011-01-28
JP2010523497A (ja) 2010-07-15
AU2008232690A2 (en) 2009-12-10
MX2009010223A (es) 2009-10-26
WO2008121748A3 (en) 2009-09-11
IL201234A0 (en) 2010-05-31
EP2129220A2 (en) 2009-12-09
US7691869B2 (en) 2010-04-06
KR20100014397A (ko) 2010-02-10
CA2680075A1 (en) 2008-10-09
US20080242673A1 (en) 2008-10-02
US7723343B2 (en) 2010-05-25
AU2008232690A1 (en) 2008-10-09
CN101652067A (zh) 2010-02-17
US20080242672A1 (en) 2008-10-02
WO2008121748A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
BRPI0808438A2 (pt) Composto, composição farmacêutica, e, usos de uma composição farmacêutica, e de um composto.
ES2237576T3 (es) Antagonistas del receptor a2a de adenosina.
RU2632870C2 (ru) Трициклические гетероциклические соединения и ингибиторы jak
ES2258164T3 (es) Antagonistas del receptor a2a de adenosina.
ES2719327T3 (es) Inhibidores de IDO
ES2381212T3 (es) 4,5-Dihidro-[1,2,4]triazolo[4,3-F]pteridinas como inhibidores de la proteincinasa PLK1 para el tratamiento de trastornos proliferativos
ES2336435T3 (es) Antagonista del receptor de adenosina a2a.
AU2016204879A1 (en) CDK Inhibitors
JP2011529918A (ja) Ｊａｋ３阻害剤としてのピペリジン誘導体
RU2600327C2 (ru) Имидазопиразины
ES2283625T3 (es) Antagonistas del receptopr a2a de adenosina de (1,2,4)-triazol biciclicos.
ES2327145T3 (es) Anatagonistas del receptor de adenosina a2a de pirazolo(1,5-a)pirimidina sustituidos.
BRPI0806811A2 (pt) derivados de purina
CZ288944B6 (cs) Derivát 5H-thiazolo[3,2-a]pyrimidinu, způsob jeho přípravy, meziprodukt pro jeho přípravu a farmaceutický prostředek, který ho obsahuje
WO2010034740A1 (en) (r)-3-(n,n-dimethylamino)pyrrolidine derivatives
CN104418842A (zh) 取代的吲哚化合物及其使用方法和用途
JP4194539B2 (ja) アゾロトリアジン類およびアゾロピリミジン類
ES2331144T3 (es) Derivados de isoxazolina-indol con actividad antipsicotica y ansiolitica mejorada.
US8785453B2 (en) Arylpiperazine-containing purine derivatives and uses thereof
HK1064100B (en) Adenosine a 2a receptor antagonists
HK1108882B (en) Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.